These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30231744)

  • 61. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The FDA's assessment of follow-on protein products: a historical perspective.
    Woodcock J; Griffin J; Behrman R; Cherney B; Crescenzi T; Fraser B; Hixon D; Joneckis C; Kozlowski S; Rosenberg A; Schrager L; Shacter E; Temple R; Webber K; Winkle H
    Nat Rev Drug Discov; 2007 Jun; 6(6):437-42. PubMed ID: 17633790
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials.
    Khin NA; Kronstein PD; Yang P; Ishida E; Hung HM; Mathis MV; Unger EF; Temple RJ
    J Clin Psychiatry; 2015 Aug; 76(8):1060-3. PubMed ID: 26214346
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
    Lapteva L; Pariser AR
    J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Information to Improve Public Perceptions of the Food and Drug Administration (FDA's) Tobacco Regulatory Role.
    Osman A; Kowitt SD; Sheeran P; Jarman KL; Ranney LM; Goldstein AO
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29661991
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Heckler v. Chaney.
    U.S. Supreme Court
    Wests Supreme Court Report; 1985 Mar; 105():1649-68. PubMed ID: 12041278
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
    Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
    Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
    Schwieterman WD
    Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146
    [TBL] [Abstract][Full Text] [Related]  

  • 69. How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities.
    Tyner KM; Zheng N; Choi S; Xu X; Zou P; Jiang W; Guo C; Cruz CN
    AAPS J; 2017 Jul; 19(4):1071-1083. PubMed ID: 28421428
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluating the Use of KIM-1 in Drug Development and Research Following FDA Qualification.
    Chen R; Sanyal S; Thompson A; Ix JH; Haskins K; Muldowney L; Amur S
    Clin Pharmacol Ther; 2018 Dec; 104(6):1175-1181. PubMed ID: 29761868
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmaceutical trademarks: navigating through the FDA's pilot program.
    Ferrer E
    Drug News Perspect; 2010 Jun; 23(5):333-6. PubMed ID: 20603657
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Factors Associated with Grade Appeals: A Survey of Psychiatry Clerkship Directors.
    Thomas LA; Milburn N; Kay A; Hatch E
    Acad Psychiatry; 2018 Jun; 42(3):354-356. PubMed ID: 28776145
    [TBL] [Abstract][Full Text] [Related]  

  • 73. One hundred years of drug regulation: where do we go from here?
    Woosley RL
    Annu Rev Pharmacol Toxicol; 2013; 53():255-73. PubMed ID: 23072378
    [TBL] [Abstract][Full Text] [Related]  

  • 74. FDA's Expedited Programs and Their Impact on the Availability of New Therapies.
    Damle N; Shah S; Nagraj P; Tabrizi P; Rodriguez GE; Bhambri R
    Ther Innov Regul Sci; 2017 Jan; 51(1):24-28. PubMed ID: 30235999
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
    Alder HC
    Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evidentiary Support in Public Comments to the FDA's Center for Tobacco Products.
    Hemmerich N; Klein EG; Berman M
    J Health Polit Policy Law; 2017 Aug; 42(4):645-666. PubMed ID: 28483810
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action.
    Brinker AD; Beitz J
    Am J Hematol; 2002 Aug; 70(4):313-7. PubMed ID: 12210813
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Food and drug administration approval process for dermatology drugs in the United States.
    Boozalis E; Semenov YR; Kwatra SG
    J Dermatolog Treat; 2018 Sep; 29(6):536-538. PubMed ID: 29304565
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Enrollee appeals of preservice coverage denials at 2 Health Maintenance Organizations.
    Studdert DM; Gresenz CR
    JAMA; 2003 Feb; 289(7):864-70. PubMed ID: 12588270
    [TBL] [Abstract][Full Text] [Related]  

  • 80. What's next after 50 years of psychiatric drug development: an FDA perspective.
    Laughren TP
    J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.